1. Introduction {#section0005}
===============

Acute respiratory tract infections (ARTI) are a major cause of morbidity and mortality worldwide, particularly in children, who may experience multiple infections per year until they are 10 years of age ([@bib11]). Viruses are responsible for the majority of ARTI, with rhinoviruses (HRV), respiratory syncytial virus (RSV), influenza virus (INF) and parainfluenzaviruses (PIV) considered the major pathogens. Traditionally, the diagnosis of these infections relied on the isolation and identification of the viral agent by cell culture or detection of viral antigens by direct immunofluorescent assays (DFA) ([@bib11]). However, using these methods a large proportion of respiratory infections remained undiagnosed.

Recent advances in molecular biology, particularly the introduction of the polymerase chain reaction (PCR) assay, have greatly improved the detection of viral respiratory pathogens. Yet, even with the most sensitive molecular techniques, only 40--60% of infections were able to be associated consistently with a causative microorganism ([@bib84]). This suggested that additional respiratory pathogens were likely to exist ([@bib128]). In fact, since 2001, seven previously undescribed viruses have been identified by analysis of clinical specimens from the human respiratory tract ([Table 1](#tbl1){ref-type="table"} ). These are human metapneumovirus (HMPV) in 2001([@bib128]), three new human coronaviruses (HCoV); the severe acute respiratory syndrome (SARS) associated coronavirus in 2003 ([@bib73]), coronavirus NL63 (NL63) in 2004 ([@bib131]), coronavirus HKU1 (HKU1) in 2005 ([@bib144]), as well as human bocavirus (HBoV) in 2005 ([@bib5]) and the recently described human polyomaviruses KI (KIV) and WU (WUV) in 2007 ([@bib6], [@bib54]). These new viral agents were detected by novel molecular methods such as VIDISCA ([@bib131]), pan-viral DNA microarrays ([@bib138]), and high throughput sequencing ([@bib5], [@bib6], [@bib54]) ([Fig. 1](#fig1){ref-type="fig"} ). These methods were comprehensively reviewed by [@bib9]. More broadly, the advent of these new technologies has greatly stimulated efforts to identify novel viruses in the respiratory tract and in other human disease states.Table 1Summary of distribution, clinical association and methods of discovery of newly emerging viruses associated with the human respiratory tractVirusPatient groupPrevalenceClinical signsMethod of discoveryReferenceHuman metapneumovirusChildren and the elderly3--25%Bronchiolitis, pneumonia, bronchitis, rhinorrhoea, cough, sore throatVirus isolation, electron-microscopy, and random PCR[@bib128]Severe acute respiratory syndrome (SARS)All agesSporadicPneumoniaVirus isolation, electron-microscopy, and consensus coronavirus PCR[@bib73]Coronavirus NL63 and coronavirus HKU1Children and the elderly1--10%Bronchiolitis, pneumonia, rhinorrhoea, fever, cough, wheezingVirus isolation, VIDISCA consensus coronavirus PCR[@bib131], [@bib144]Human bocavirusChildren1--11%Bronchiolitis,[a](#tbl1fn1){ref-type="table-fn"} pneumonia, acute otitis media, asthmaRandom PCR[@bib5]Polyomavirus KI and polyomavirus WUChildren1--7%Bronchiolitis,[a](#tbl1fn1){ref-type="table-fn"} pneumonia, coughRandom PCR[@bib6], [@bib54][^1]Fig. 1(A) VIDISCA method. Schematic overview of the stages incorporated in the performance of the VIDISCA method (adapted from [@bib131]). (B) Random PCR. Primer 1 with a unique 5′-end and degenerate 3′-end sequence is used in a first round PCR. The degenerate segment binds to template sequences that occur stochastically throughout the viral genome, and primer extension occurs with T4 polymerase. Double-stranded DNA is formed containing unique sequences on each strand. Primer 2 hybridizes to the unique sequence and is used for amplification of fragments of the viral template DNA (adapted from [@bib122]). (C) High throughput sequencing. Randomly amplified PCR products are cloned into a suitable plasmid vector, and subsequently sequenced.

Once new viral agents are identified, it is important to establish their pathogenic potential. Traditionally, Koch\'s postulates have provided the standard for establishing a causal link between a pathogen and disease, but these have been modified over the years to match new knowledge of viral detection and disease processes ([@bib50]). These modified postulates now propose that a causal relationship between an organism and disease may be established if (i) the organism is consistently present in patients with the disease at a significantly greater prevalence than in matched control subjects, (ii) the disease may be replicated in an appropriate animal model after challenging with the viral pathogen, and subsequent isolation of the agent from the challenged animal, and (iii) a specific immune response to the virus by the host can be demonstrated.

The process of establishing a causal link between a new virus and disease may be aided by the availability of a well-characterized specimen bank. Such specimens collected from patients with a variety of illnesses, supported with comprehensive clinical and epidemiologic data, are a valuable resource for establishing an association between presence of a virus and disease. However, the conclusion about such an association is only valid if they are tested together with appropriately matched controls.

Of the viruses discovered over the last 7 years, HMPV and the newly emerging HCoV are recognized to have global presence, and are considered causative agents of respiratory disease. However, to date, SARS coronavirus has been restricted geographically and has only been associated with limited and sporadic outbreaks of human disease. Of the other emerging viruses, an association with the respiratory tract, or respiratory infection, has been postulated, but not proven. These are HBoV and the newly described KIV and WUV.

This review examines the state of knowledge of newly emerging viruses that have been detected in the human respiratory tract, and their clinical association with human disease.

2. Human metapneumovirus {#section0010}
========================

HMPV is a new human respiratory tract pathogen first described in 2001. The virus was isolated by cell culture from respiratory secretions collected during a 20-year period from Dutch children with ARTI. HMPV showed slow replication in cell culture with characteristic syncytia formation followed by rapid internal disruption of the cells at 10--14 days after inoculation ([@bib128]).

It was established that HMPV was a respiratory pathogen of primates, by demonstrating active replication of the virus in four juvenile cynomolgus macaques, resulting in mild upper respiratory tract signs in two of these animals.

The HMPV genome was characterized using random arbitrarily primed-PCR, and the virus was subsequently classified within *Paramyxoviridae* based on genome structure and organization. HMPV is the first known mammalian metapneumovirus associated with disease.

Many studies have shown a broad spectrum of clinical signs associated with HMPV infection in patients of all age groups. Like other human respiratory viruses, HMPV may cause upper and lower respiratory tract infection in infants and young children ([@bib139], [@bib142]). It is second only to RSV as a cause of bronchiolitis in early childhood ([@bib20], [@bib51], [@bib129], [@bib135], [@bib98], [@bib139], [@bib27], [@bib115]). Children younger than 5 years of age are most susceptible to HMPV infection ([@bib130]), and those younger than 2 years of age are most likely to be hospitalized with severe symptoms, including bronchiolitis, pneumonia, and bronchitis ([@bib65], [@bib62]). Recently, [@bib62] showed that acute otitis media developed in 61% of HMPV-infected children younger than 3 years of age. There are no clinical manifestations of HMPV infection that are unique, and infection in young children cannot be distinguished from infection with RSV or INF ([@bib108], [@bib13], [@bib21], [@bib41], [@bib94], [@bib130], [@bib139], [@bib136]). Several studies have reported the association of HMPV and asthma exacerbations in children ([@bib137], [@bib139], [@bib141], [@bib136]), and with exacerbations of both asthma and chronic obstructive pulmonary disease (COPD) in adults ([@bib45]).

HMPV infection in adults usually presents with mild common cold-like respiratory symptoms such as rhinorrhoea, cough and sore throat ([@bib123], [@bib44]). However, disease may be more severe in patients with underlying medical conditions such as cardiopulmonary disease, the elderly and immunocompromized subjects ([@bib20], [@bib44], [@bib59], [@bib64]). In these subjects the virus can cause prolonged and serious infections, and several case studies have described the detection of HMPV in patients with severe lung disease including several fatalities ([@bib107], [@bib24], [@bib41], [@bib76], [@bib93], [@bib140]). Interestingly, one study reported an immunocompromized child, in whom HMPV infection with two different strains of the virus were detected during a 10-month period ([@bib140]).

It is now recognized that HMPV has a global distribution ([@bib128], [@bib20], [@bib22], [@bib102], [@bib31], [@bib40], [@bib51], [@bib89], [@bib106], [@bib32], [@bib36], [@bib4], [@bib71], [@bib85], [@bib104], [@bib111], [@bib53], [@bib57], [@bib113]) circulating predominantly in late winter and spring. Usually the peak of infection is coincident with or follows the peak of RSV infection ([@bib21], [@bib68], [@bib105], [@bib106], [@bib41], [@bib72], [@bib98], [@bib23], [@bib27], [@bib2], [@bib66], [@bib101], [@bib114]). Many respiratory viruses share seasonality and susceptible populations. As a result, co-detection of HMPV with other respiratory viruses has been reported at rates ranging from 1% to greater than 10% ([@bib135], [@bib41], [@bib139], [@bib147]). One study reported that dual infection with HMPV and RSV is associated with severe bronchiolitis and significantly increased the risk of admission to a paediatric intensive-care unit ([@bib117]). This is at odds with previous findings which failed to detect a predisposition to more severe disease in patients with multiple respiratory virus detections ([@bib83]).

Two major genotypes of HMPV, designated A and B are recognized, each with two subtypes (A1 and A2; B1 and B2) ([@bib108], [@bib18], [@bib41], [@bib87], [@bib139], [@bib27], [@bib136]). Circulating strains of HMPV differ in different populations at any single time, and the same strain may be present in geographically distinct locations in different years. In an Australian study, the predominant genotype of HMPV switched over 4 consecutive years from genotype A1 to A2 to B1 ([@bib119]). Similar observations have been reported elsewhere ([@bib55]). So far there are no data to suggest that severity of illness may be associated with a specific genotype ([@bib65]).

Seroprevalence studies have shown that the presence of HMPV-specific antibodies was greater than 90% by age 5 years, and nearly 100% in adults ([@bib128], [@bib82]). This suggests that primary infection with HMPV occurs early in childhood, typically between the ages of 1--5 years ([@bib128], [@bib35], [@bib143], [@bib82]). The reported seroprevalence in infants younger than 3 months of age was greater than 90%, decreasing to a minimum by age 13 months and increasing to 52% by age 2 years ([@bib143]). Although this appears to be indicative of maternally derived antibodies ([@bib82]), the role of such antibodies in the protection or moderation of HMPV infection remains to be determined.

3. Emerging human coronaviruses {#section0015}
===============================

Coronaviruses (CoV) infect many species of animals, including humans. The first HCoV, of which 229E and OC43 are the representatives, were identified in the 1960s ([@bib125], [@bib60], [@bib95]). Coronaviruses are classified into three distinct groups, with 229E and NL63 included in Group 1 coronaviruses and OC43 and HKU1 in Group 2 ([@bib75]). SARS--CoV, represents an early split from Group 2 coronaviruses ([@bib39], [@bib92], [@bib112], [@bib121]) and is believed to have originated from wild animals ([@bib58], [@bib77]).

3.1. SARS coronavirus {#section0020}
---------------------

First reports of an outbreak of a new respiratory illness involving "atypical pneumonia" were published in 2003 ([@bib25]; [@bib124]). The novel virus present in these cases was isolated from patients' lungs and sputa on Vero E6 cells ([@bib33], [@bib34], [@bib106], [@bib73]). Sequencing of the viral isolate showed the presence of a new human coronavirus ([@bib112], [@bib121]). It was demonstrated that this virus was the aetiologic agent for SARS by transmission of respiratory disease to nonhuman primates ([@bib47]). The SARS epidemic was halted by a highly effective global public health response co-ordinated by the World Health Organization, and there is no evidence that SARS--CoV is currently circulating in humans. However, the SARS outbreak focussed renewed attention on coronaviruses generally, resulting in the identification of two more human coronaviruses, NL63 and HKU1.

3.2. Human coronaviruses NL63 and HKU1 {#section0025}
--------------------------------------

HCoV--NL63 was first detected in 2004 in a child with bronchiolitis in The Netherlands ([@bib131]), whilst HCoV--HKU1 was detected in 2005 in an adult with chronic pulmonary disease in Hong Kong ([@bib144]). After the initial discovery, several groups have reported presence of these viruses in their populations illustrating global presence ([@bib48], [@bib10], [@bib14], [@bib29], [@bib37], [@bib67], [@bib97], [@bib30], [@bib43], [@bib56], [@bib120], [@bib126], [@bib127]). These reports showed that NL63 and HKU1 may be detected in 1 to 10% of patients with acute respiratory tract infections. Co-detection of these viruses with other respiratory viruses was commonly reported ([@bib132]). Like SARS--CoV, NL63 has been successfully cultured in monkey epithelial cell lines ([@bib48], [@bib131], [@bib116]), but to date, it has not been possible to culture HCoV--HKU1, despite attempts to do so in many cell lines. This difficulty with isolating some newly identified viruses particularly explains why they have not previously been detected.

Initial studies described the presence of NL63 in young children admitted to hospital with severe lower respiratory tract infections (LRTIs) ([@bib48], [@bib131]), but the virus has also been detected in elderly patients with a fatal outcome, showing that the severity of the respiratory disease can be substantial ([@bib14]).

HCoV--NL63 was proven to be a respiratory pathogen and has been identified as an agent of laryngotracheitis (croup) ([@bib46], [@bib72], [@bib133]). In a case-controlled study of young German children it was reported that the chance of croup is 6.6 times higher in NL63-positive children than in NL63-negative children ([@bib46], [@bib72]). Also, a link between NL63 and Kawasaki disease has been suggested ([@bib42]), but other groups recently questioned this association ([@bib17], [@bib38], [@bib118], [@bib12], [@bib26]).

The first described HKU1 cases were amongst elderly patients and children with major underlying disease ([@bib145]). Similar findings in the USA ([@bib43]) and France ([@bib127]) suggested that HKU1 infection may aggravate the conditions of persons with an underlying disease, thereby resulting in hospitalization.

Common respiratory symptoms accompanying HKU1 infection are rhinorrhoea, fever, coughing, wheezing, and disease manifestations include bronchiolitis and pneumonia ([@bib78], [@bib120]). It has been suggested that HKU1 might also be involved in gastrointestinal disease ([@bib127]).

HKU1 and NL63 infections are generally not life threatening, certainly not in otherwise healthy persons. This suggests that these coronaviruses, like 229E and OC43, are predominantly common cold viruses that can cause more severe clinical symptoms in young children, elderly persons, and the immunocompromized ([@bib96], [@bib63], [@bib134]).

Phylogenetic analysis has shown that NL63 may be classified into two genotypes ([@bib131], [@bib10], [@bib29], [@bib126]), and full-genome sequencing of HKU1 isolates has also revealed the presence of two genotypes (A and B) with the possibility of a third genotype (C) that is the resultant of recombination between genotypes A and B ([@bib146]).

4. New viruses identified in the respiratory tract of humans {#section0030}
============================================================

4.1. Human bocavirus {#section0035}
--------------------

Human bocavirus was first described in 2005 ([@bib5]). This virus was identified by a procedure based on DNase treatment of pooled respiratory samples, random amplification and cloning, followed by large-scale sequencing and bioinformatic analyses. In their original study, [@bib5] showed HBoV had a prevalence of 3.1% in Swedish children with LRTI. Soon thereafter, a second study from Australia reported a 5.2% prevalence of HBoV in respiratory samples collected from children with ARTI during winter ([@bib120]). In a study of hospitalized patients, [@bib11] detected HBoV in 5.6% of children, showing a peak prevalence of infection in spring. Subsequently, presence of the virus has been reported by investigators in Europe, the United Kingdom, the United States, Canada, Asia, and Australia, with prevalence rates ranging from 1.5% to 11.3% in these populations ([@bib5], [@bib11], [@bib15], [@bib16], [@bib30], [@bib49], [@bib69], [@bib86], [@bib91], [@bib120], [@bib52], [@bib90], [@bib99], [@bib100]). However, the results from these studies, regarding seasonality, indicate that there is no obvious regular seasonal occurrence of HBoV. A common feature of these studies was that HBoV was most frequently detected in infants younger than 3 years of age.

[@bib11] proposed an association between detection of HBoV in the upper respiratory tracts of children and LRTI. They demonstrated that presence of HBoV in the upper respiratory tract was positively associated with asthma, acute otitis media, and pneumonia. The most common signs observed in HBoV-infected children were respiratory distress and hypoxia associated with a diagnosis of bronchiolitis, supporting the concept that HBoV may directly infect the lower respiratory tract.

Recent studies reporting an association of HBoV with ARTI, differed from other similar studies by including control populations ([@bib69], [@bib91], [@bib52], [@bib90]). HBoV was detected at high frequency in subjects with overt disease, whereas the virus was either not found or was found very infrequently in control subjects. Although a positive association with ARTI was suggested, the results remain inconclusive, given the high rate at which other viruses were detected in HBoV-positive specimens. These findings add important corroborative support, but still do not prove causality of disease.

In a similar study using control subjects, [@bib7] proposed HBoV as a cause of acute wheezing in children. However, differences in specimen type, age groups, and time of year tested for controls and test subjects were considerable and may have confounded detection rates in this study.

HBoV has only rarely been detected in immunocompetent adult subjects ([@bib15]) yet was frequently detected in immunosuppressed adults ([@bib74], [@bib91], [@bib90]). However, the presence of HBoV in these subjects may be the result of re-infection, viral persistence or reactivation ([@bib8]). To answer these questions, prospective longitudinal examination of HBoV in immunosuppressed patients will be an important area for future studies.

The idea that HBoV infection may play a possible role in gastroenteritis has been suggested because of the frequent manifestation of gastrointestinal symptoms in HBoV-positive subjects. Several studies have examined an association of HBoV with gastrointestinal disease, and have reported HBoV presence in faeces with a prevalence rate ranging from 0.8% to 9.1% in these patients ([@bib79], [@bib81], [@bib100], [@bib136]). Also, [@bib3] reported the detection of HBoV in Brazilian children with gastroenteritis in the absence of respiratory symptoms. Although these findings suggest that HBoV may play a role as an agent of acute gastroenteritis, it is possible that this is a clinical presentation of a systemic response to HBoV infection by the host. This data however, does add new knowledge about potential mechanisms of transmission for this virus.

So far, two slightly different genetic lineages of HBoV have been reported globally that share greater than 98% amino acid identity ([@bib5], [@bib69], [@bib16], [@bib28], [@bib100]). Also, [@bib79] reported a high level of genomic conservation of HBoV detected in samples from different anatomical sites, showing that a single lineage of HBoV was found in both respiratory tract and enteric specimens. Similarly, HBoV detected in patients over a 21-month period showed little genetic variation within the *NP-1* and *NS1* genes ([@bib11]).

4.2. Novel human polyomaviruses KIV and WUV {#section0040}
-------------------------------------------

Recently, two new human polyomaviruses, KIV and WUV were detected in respiratory tract specimens ([@bib6], [@bib54]). The viruses were identified following large-scale molecular screening using high throughput DNA sequencing of random clones.

KIV and WUV are related members of a new group (or possibly sub-family) within the *Polyomaviridae*, small DNA viruses with circular, covalently closed double-stranded genomes infecting a wide range of mammalian and avian species. Polyomaviruses frequently establish persistent, lifelong infections characterized by highly restricted or latent infection.

In their initial reports [@bib6] detected KIV in 1% of nasopharyngeal aspirates and 0.5% of stool samples collected from a Swedish population and [@bib54] reported a prevalence of 3% and 0.6% for WUV in respiratory samples from Australia and the USA, respectively. Neither group was able to detect these viruses in urine samples.

Since these first reports, KIV and WUV DNA have been detected in respiratory specimens from a number of geographic locations, suggesting a global presence for these viruses. Studies from Australia and Scotland reported a prevalence for KIV of 2.5% and 1.4%, respectively ([@bib19], [@bib103]), and for WUV prevalence rates ranged from 1% in a Scottish population to 7% in Australian and South Korean populations ([@bib19], [@bib61], [@bib103]).

One striking feature of early findings concerning KIV and WUV is their high rate of co-detection with other respiratory viruses. A co-detection rate of 74% has been observed for KIV ([@bib19]) and rates ranging from 68% to 79% for WUV ([@bib19], [@bib61], [@bib80]). A level of 10% co-detection of KIV with WUV in the absence of any other respiratory virus was reported by [@bib19].

Although an aetiologic role in childhood respiratory disease has been proposed for KIV and WUV ([@bib6], [@bib19], [@bib54]), initial investigations have been based on large-scale screening of respiratory samples referred for general diagnostic testing from patients with moderate to severe respiratory disease. It is however difficult to assess the pathogenic role of these viruses without examining samples collected from matched control populations. Three recent studies have sought to do this for WUV, reporting prevalence rates in symptomatic versus asymptomatic subjects of 7.0% versus 4.2% ([@bib61]), 2.5% versus 6.4% ([@bib1]) and 1.0% versus 5.4% ([@bib103]). However, these data must be interpreted with caution as each of these studies examined only small numbers of controls and some of these were not well matched to the symptomatic population tested. Interestingly, although [@bib103] reported a high prevalence of KIV (5.4%) and WUV (5.4%) in their control subjects, 5 of the 6 (83%) positive specimens came from subjects who were classified as immunosuppressed. If consistent, the presence of KIV and WUV in control populations may represent a latent or persistent infection with subsequent asymptomatic reactivation or prolonged shedding from a prior respiratory tract infection.

Persistent shedding of WUV over a 6--8 week period was amongst a number of interesting observations reported in two children (1.5 and 4 years old) from St. Louis, USA, and WUV was also the only virus detected in a 1-day-old infant with respiratory symptoms raising interesting questions about possible transmission mechanisms of this virus ([@bib80]).

To date, little information is available regarding the molecular diversity of KIV and WUV strains present in different populations. Early data from Australian, USA and Canadian WUV-positive samples showed limited or no genetic variations based on sequencing from the large TAg region and the VP2 region ([@bib1], [@bib54]). This was substantiated by whole genome analysis of Australian and USA samples which confirmed limited sequence variation amongst KIV and WUV strains from those patient groups ([@bib19]).

Further studies will need to be completed before the role of KIV and WUV as respiratory pathogens can be confirmed. It remains possible that these viruses are not involved in respiratory disease and their presence in the respiratory tract simply reflects their mode of transmission. However, considering the oncogenic potential of polyomaviruses in mammals, linking KIV and WUV to a particular disease will be important and may have significant medical implications.

5. Conclusion {#section0045}
=============

With the development of new molecular technology, our ability to detect and characterize new viral agents has greatly improved. As a result, genome sequences have been described for new viruses that are associated with the human respiratory tract, gastrointestinal tract as well as new blood-borne viruses. Some of these are recognized as significant human pathogens causing disease in certain population groups. Others can be found in clinical specimens without definitive evidence for their role as the causative agent of disease, and yet others, like TT-(torqueteno) virus ([@bib88], [@bib109]) and mimivirus ([@bib70], [@bib110]) have been loosely associated with respiratory disorders in humans.

Many putative viral respiratory pathogens could not be isolated from patients with overt disease, and researchers have as yet been unable to satisfy the modified Koch\'s postulates that will prove a causal relationship. It is important therefore, that further extensive clinical studies be continued in an attempt to define the role of these agents as human pathogens.

Still, for a significant proportion of clinical infectious disease of suspected viral origin, a pathogen cannot be identified. Although new molecular methods are increasingly used to investigate these unknown causes of disease, they remain technically challenging and prone to the amplification of non-viral related sequence artefacts. However, with continuing advances in molecular technology and the development of more reliable, robust and reproducible molecular techniques, it seems certain that new potential viral pathogens of humans will be discovered.

[^1]: Currently there is no definitive evidence that bocavirus and polyomaviruses KIV and WUV are causative agents of respiratory disease.
